UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Non-Hodgkin lymphoma is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).
The main purpose of this study is to test the safety of an oral drug, ibrutinib, added to the standard lymphoma treatment.
We will also study whether ibrutinib has a helpful effect against HIV and other viruses in our bodies that can cause lymphoma.
If you meet all of the criteria for being in the study, you will be registered to participate. Trial participation includes one-5 day inpatient stay each treatment cycle. Each treatment cycle is 21 days.
- Study Identifier: 828995